Indevus Sanctura Comparative Claims Not Supported By NDA, FDA Finds
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Indevus’ NDA for Sanctura did not support a claim that trospium has a superior central nervous system adverse event profile to other anticholinergics, FDA review documents indicate.